Fig. 7: In vivo combination of ceritinib and anti-PD-1. | Cell Death & Disease

Fig. 7: In vivo combination of ceritinib and anti-PD-1.

From: Pharmacological inhibitors of anaplastic lymphoma kinase (ALK) induce immunogenic cell death through on-target effects

Fig. 7

One million of murine NPM1-ALK+ R80 cells were injected into the right flank of syngeneic mice (C57BL/6). When tumors reached a surface of 30–35 mm2 mice were randomized and treated with ceritinib (CER, 50 mg/Kg, i.p.) or vehicle control on the day of the randomization (d0) and 2 days later (d2). Then, on d8, d12, d16 mice were injected i.p. with 200 μg of anti-PD-1 or isotype control antibodies (A). Tumor surface is represented as mean ± SEM of mice belonging to the same group (B) or for single mice (C). Survival is depicted in D. Vehicle + isotype n = 8; vehicle + anti-PD-1 n = 8; CER + isotype n = 9; CER + anti-PD-1 n = 9. Comparison between tumor growth curves was assessed using a type II ANOVA test, while statistical significance of survival data was calculated using the Log-rank test. ns non-significant.

Back to article page